Response Predictors in Chronic Migraine: Medication Overuse and Depressive Symptoms Negatively Impact Onabotulinumtoxin-A Treatment

Background: Despite numerous studies that have investigated clinical, radiological, and biochemical response predictors, the clinical profile of those patients who might benefit from OnabotulinumtoxinA is still missing. The aim of the present study was to identify potential OnabotulinumtoxinA response predictors among several clinical characteristics and confirm OnabotulinumtoxinA efficacy and safety in chronic migraine (CM) prevention. Methods: The study was conducted at the Headache Center—Neurology Clinic—Spedali Civili Hospital of Brescia. Eighty-four consecutive CM patients were enrolled, with a mean age of 48 years (SD 9.7) and a mean disease duration of 10.1 years (SD 6.6). The mean reported headache-days frequency was 22.5 (SD 5.9) per month, while the mean number of severe headache-days was 15.2 (SD 8.9) with a mean monthly medication intake of 33.2 (SD 5.6). The clinical characteristics analyzed as potential response predictors were: gender, disease duration, migraine characteristics (location, side constancy, unilateral autonomic and neurovegetative symptoms), previous prophylactic treatments, add-on therapies, withdrawal therapies, psychiatric (anxiety and depression symptoms) comorbidities and medication overuse. Results: A significant reduction from baseline to 3, 6, 9, and 12 month treatment cycles in total headache days, high intensity headache days and triptans consumption per month was found. Depressive symptoms and medication overuse negatively predicted OnabotulinumtoxinA outcome. Conclusions: Our results confirm the efficacy and safety of OnabotulinumtoxinA in CM. Depressive comorbidity and medication overuse, among all clinical variables, were the only significant response predictors. Such findings provide interesting insights regarding patients selection for OnabotulinumtoxinA treatment as, with the introduction of anti calcitonin gene-related (CGRP) monoclonal antibodies, clinicians will have to thoroughly judge and tailor among the many available therapeutic options now available. Future research might be needed to confirm our findings, in particular for its therapeutic implications.

[1]  S. Tepper,et al.  Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[2]  Lauren R Natbony,et al.  Episodic Migraine Comorbidities: Avoiding Pitfalls and Taking Therapeutic Opportunities , 2019, Current Pain and Headache Reports.

[3]  P. Pozo‐Rosich,et al.  OnabotulinumtoxinA: An Effective Tool in the Therapeutic Arsenal for Chronic Migraine With Medication Overuse , 2018, Front. Neurol..

[4]  J. Olesen.  International Classification of Headache Disorders , 2018, The Lancet Neurology.

[5]  A. Blumenfeld,et al.  Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study , 2018, The Journal of Headache and Pain.

[6]  M. Gallego,et al.  OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study , 2018, European journal of neurology.

[7]  T. Sobrino,et al.  CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study , 2018, Headache.

[8]  L. Pini,et al.  Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy , 2017, Front. Neurol..

[9]  F. Amoozegar.  Depression comorbidity in migraine , 2017, International review of psychiatry.

[10]  M. de Tommaso,et al.  Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers , 2017, The Journal of Headache and Pain.

[11]  Ryan M. Smith,et al.  Brain Changes in Responders vs. Non-Responders in Chronic Migraine: Markers of Disease Reversal , 2016, Front. Hum. Neurosci..

[12]  C. Pasquarella,et al.  The use of onabotulinum toxin A (Botox®) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study , 2016, Neurological Sciences.

[13]  D. Boomsma,et al.  Genetic epidemiology of migraine and depression , 2016, Cephalalgia : an international journal of headache.

[14]  M. Copetti,et al.  P025. Two-year follow-up with OnabotulinumtoxinA for chronic migraine: a real life evaluation of 113 patients , 2015, The Journal of Headache and Pain.

[15]  G. Zanchin,et al.  O051. Chronic migraine and onabotulinumtoxinA: a prospective study on patients treated at the Headache Centre of the Padua University and analysis of possible predictors of responsivity , 2015, The Journal of Headache and Pain.

[16]  R. Lipton,et al.  The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results , 2015, Cephalalgia : an international journal of headache.

[17]  P. Barbanti,et al.  Pharmacological Trials in Migraine: It's Time to Reappraise Where the Headache Is and What the Pain Is Like , 2015, Headache.

[18]  R. Lipton,et al.  Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety , 2015, International journal of general medicine.

[19]  David W Dodick,et al.  Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[20]  D. Guidetti,et al.  Migraine and Stroke: “Vascular” Comorbidity , 2014, Front. Neurol..

[21]  M. Khalil,et al.  Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK , 2014, The Journal of Headache and Pain.

[22]  C. Kao,et al.  Association between migraine and irritable bowel syndrome: a population‐based retrospective cohort study , 2014, European journal of neurology.

[23]  P. Martínez-Camblor,et al.  CGRP and VIP Levels as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine , 2014, Headache.

[24]  R. Cady,et al.  An Exploratory Study of Salivary Calcitonin Gene‐Related Peptide Levels Relative to Acute Interventions and Preventative Treatment With OnabotulinumtoxinA in Chronic Migraine , 2014, Headache.

[25]  Yen-Feng Wang,et al.  Efficacy, safety, and predictors of response to botulinum toxin type A in refractory chronic migraine: A retrospective study , 2014, Journal of the Chinese Medical Association : JCMA.

[26]  B. Seifert,et al.  Patients profiling for Botox® (onabotulinum toxin A) treatment for migraine: a look at white matter lesions in the MRI as a potential marker , 2013, SpringerPlus.

[27]  R. Lipton,et al.  Psychiatric comorbidities of episodic and chronic migraine , 2013, Journal of Neurology.

[28]  R. Ohrbach,et al.  The International Classification of Headache Disorders, 3rd edition (beta version) , 2013, Cephalalgia : an international journal of headache.

[29]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[30]  V. Gudnason,et al.  Migraine, depression, and brain volume , 2013, Neurology.

[31]  S. Aurora,et al.  OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56‐Week PREEMPT Clinical Program , 2011, Headache.

[32]  F. Brighina,et al.  Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study , 2011, The Journal of Headache and Pain.

[33]  R. Lipton,et al.  Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS) , 2011, Cephalalgia : an international journal of headache.

[34]  M. Brin,et al.  OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program , 2010, Headache.

[35]  R. Lipton,et al.  Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[36]  D. Buchwald,et al.  A Twin Study of Depression and Migraine: Evidence for a Shared Genetic Vulnerability , 2009, Headache.

[37]  R. Lipton,et al.  Chronic migraine in the population , 2008, Neurology.

[38]  J. Olesen.  The International Classification of Headache Disorders , 2008, Headache.

[39]  S. Akerman,et al.  Dopamine and Migraine: Biology and Clinical Implications , 2007, Cephalalgia : an international journal of headache.

[40]  N. Mathew,et al.  Predictors of Response to Botulinum Toxin Type A (BoNTA) in Chronic Daily Headache , 2007, Headache.

[41]  L. Arendt-Nielsen,et al.  Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A , 2007, PAIN.

[42]  T. Ward,et al.  Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A , 2006, Pain.

[43]  A. Srikiatkhachorn,et al.  Serotonin Depletion, Cortical Spreading Depression, and Trigeminal Nociception , 2006, Headache.

[44]  Steven S. Sharfstein,et al.  The American Psychiatric Association , 2005, International psychiatry : bulletin of the Board of International Affairs of the Royal College of Psychiatrists.

[45]  D. Dodick,et al.  Duration of Migraine Is a Predictor for Response to Botulinum Toxin Type A , 2005, Headache.

[46]  Shuo Qian,et al.  Migraine and stroke , 1995, Stroke and Vascular Neurology.

[47]  N. Breslau,et al.  Migraine and Major Depression: A Longitudinal Study , 1994, Headache.

[48]  M. Arnold.  Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition , 2018, Cephalalgia : an international journal of headache.